MedPath

The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

Registration Number
NCT00732654
Lead Sponsor
Johns Hopkins University
Brief Summary

The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Are age 6 to 21 years
  • Provide signed informed consent (by parent or legal guardian if the subject is a minor), and informed assent if applicable
  • Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper or lower respiratory symptoms, GI disturbances, other rash or oral symptoms)
  • Have a positive skin prick test (defined as wheal 3 mm ≥ negative control) and cow's milk- immunoglobulin E (IgE) > 0.35 kilo Immunoglobulin Units (kIU)/L
  • Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of cow's milk intact protein (2,400 mg total milk protein).
  • Are using appropriate birth control if subject is female and of child bearing age.
  • Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home
Read More
Exclusion Criteria
  • Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 ≤ 92% at any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence
  • Have a history of intubation related to asthma
  • Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC
  • Are pregnant or lactating
  • Have a viral Upper Respiratory Infection (URI) or gastroenteritis within 7 days of OFC (OFC needs to be rescheduled)
  • Have pulmonary function tests <80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma
  • Are currently taking greater than medium dose inhaled corticosteroid (>400 mcg/day fluticasone or fluticasone equivalent if ≤ 12 years old or > 600 mcg/day if > 12 years old)
  • Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges
  • Have used systemic corticosteroids within 4 weeks prior to baseline visit
  • Are receiving omalizumab, beta-blocker, Angiotensin Converting Enzyome (ACE) inhibitor or tricyclic antidepressant therapy
  • Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring therapy (e.g., heart disease, diabetes)
  • Have participated in any interventional study for treatment of a food allergy in the past 12 months
  • Have a severe reaction at initial DBPCFC, defined as either:

Life-threatening anaphylaxis, or Reaction requiring hospitalization

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SLIT/ Oral Immunotherpay (OIT) BMilk Powder Immunotherapy goal dose 1000mg/dayThese subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Sublingual Immunotherapy (SLIT)Milk Protein Extract Immunotherapy goal of 7mg/dayThese subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year. Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
SLIT/ Oral Immunotherpay (OIT) BMilk Protein Extract Immunotherapy goal of 4mg/dayThese subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Sublingual Immunotherapy (SLIT)Milk Protein Extract Immunotherapy goal of 4mg/dayThese subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year. Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
SLIT/ OIT AMilk Protein Extract Immunotherapy goal of 4mg/dayThese subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years. Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
SLIT/ OIT AMilk Powder Immunotherapy goal dose 2000 mg/dayThese subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years. Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Primary Outcome Measures
NameTimeMethod
Oral Food Challenge Threshold (OFC) ThresholdChange from baseline to after therapy (up to 18 months)

mg CM protein

Change in CM-specific Immunoglobulin G4 (IgG4)Change from baseline to after therapy (up to 18 months)

Cow's milk specific IgG4 was measured at baseline and after therapy (kUa/L)

Change in End Point Skin TestChange from baseline to after therapy (up to 18 months)

Allergen provoked skin test (mm)

Change in CM-specific Immunogloblin E (IgE)Change from baseline to after therapy (up to 18 months)

Cow's milk specific IgE was measured at baseline and after therapy (kUa/L)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Duke University

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath